Related Experiment Video
Updated: May 17, 2025
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Systemic Treatment of Locally Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
Joseph Vento1, Tian Zhang1, Payal Kapur2
1Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern, Dallas, TX 75235, USA.
Abstract:
Non-clear cell renal cell carcinoma (nccRCC) represents a heterogenous group of malignancies with varying degrees of clinical aggressiveness and response to different systemic therapies. As the characterization of subtypes of nccRCC continues to evolve, it is important to understand the evidence around systemic treatments used in advanced or metastatic stages of specific subtypes. Here, we review the literature on systemic therapies in nccRCC, with a focus on prospective trials that included patients with papillary renal cell carcinoma (RCC), chromophobe RCC, RCC not further classified/unclassified RCC, translocation RCC, collecting duct RCC, and renal medullary carcinoma. We also review emerging treatments for other molecularly defined subtypes of this disease.
Insights
This review examines systemic treatments for advanced non-clear cell renal cell carcinoma (nccRCC) subtypes. It focuses on evidence from prospective trials for papillary, chromophobe, and other rare RCC types.
Area of Science:
- Oncology
- Nephrology
- Translational Research
Background:
- Non-clear cell renal cell carcinoma (nccRCC) is a diverse group of kidney cancers.
- nccRCC subtypes exhibit varied clinical behavior and treatment responses.
- Understanding subtype-specific systemic therapies is crucial for advanced or metastatic disease.
Purpose of the Study:
- To review current evidence on systemic treatments for specific nccRCC subtypes.
- To focus on prospective trials evaluating therapies in advanced/metastatic nccRCC.
- To discuss emerging treatments for molecularly defined nccRCC subtypes.
Main Methods:
- Literature review of systemic therapies in nccRCC.
- Focus on prospective clinical trials.
- Inclusion of specific nccRCC subtypes: papillary, chromophobe, unclassified, translocation, collecting duct, and renal medullary carcinoma.
Main Results:
- Summarizes findings from prospective trials for various nccRCC subtypes.
- Highlights the evidence base for current systemic treatment approaches.
- Identifies gaps and emerging trends in nccRCC therapy.
Conclusions:
- Systemic therapy effectiveness varies significantly across nccRCC subtypes.
- Further research is needed to optimize treatments for rare and molecularly defined subtypes.
- Personalized treatment strategies are essential for improving outcomes in nccRCC.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...